AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum
September 21 2017 - 7:00AM
Business Wire
AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc.
(NYSE American: BTX), announces that Chief Executive Officer
Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is
participating in a fireside chat at Cell & Gene Therapy CEO on
Monday, September 25, 2017 in Boston.
Dr. West’s fireside chat will be at 3:00pm ET/12:00pm PT with J.
Craig Venter, Ph.D., Co-Founder and Executive Chairman of Human
Longevity, Inc. and founder of Celera Genomics and the J. Craig
Venter Institute. It will be moderated by David Grainger, Ph.D.,
CEO of Methuselah Health and Partner at Medicxi.
Cell & Gene Therapy CEO is an off-the-record networking
forum that brings together CEOs and decision makers in cell
therapy, gene therapy, and regenerative medicine. Intimate
discussion panels, keynotes and fireside chats feature thought
leaders debating business model efficiencies, financing, regulatory
issues, market access and reimbursement, novel partnerships,
manufacturing, and delivery challenges. Healthcare investors and
leading researchers also participate.
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE
American: BTX), is a biotechnology company applying technology
relating to cellular immortality and regenerative biology to aging
and age-related diseases. The company has three initial areas of
product development: pluripotent stem cell-derived brown adipocytes
(AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue
Regeneration (iTR). Initial planned indications for these products
are Type 2 diabetes, cardiac ischemia, and cancer respectively.
More information on AgeX can be found on the company’s website at
www.agexinc.com.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting
three primary sectors, aesthetics, ophthalmology and cell/drug
delivery. Its clinical programs are based on two platform
technologies: pluripotent cells and cell/drug delivery. The
foundation of BioTime’s core therapeutic technology platform is
pluripotent cells that are capable of becoming any of the cell
types in the human body. The foundation of the Company’s cell
delivery platform is its HyStem® cell and drug delivery matrix
technology. BioTime also has significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc. and
OncoCyte Corporation, and one private company, AgeX
Therapeutics.
BioTime common stock is traded on the NYSE American and TASE
under the symbol BTX. For more information, please
visit www.biotimeinc.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170921005492/en/
Investor Contact:BioTimeDavid Nakasone,
510-871-4188Dnakasone@biotimeinc.comorMedia Contact for AgeX:Gotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024